Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016020732 - MODULATORS OF CASPASE-6

Publication Number WO/2016/020732
Publication Date 11.02.2016
International Application No. PCT/IB2015/000144
International Filing Date 14.02.2015
IPC
A61K 31/535 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 31/165 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61P 25/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 251/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
251Compounds containing nitrogen atoms doubly- bound to a carbon skeleton
02containing imino groups
28having nitrogen atoms of imino groups acylated
C07D 265/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
265Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
041,3-Oxazines; Hydrogenated 1,3-oxazines
06not condensed with other rings
CPC
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 251/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
251Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
02containing imino groups
28having nitrogen atoms of imino groups acylated
Applicants
  • THE UNIVERSITY OF BRITISH COLUMBIA [CA]/[CA]
  • UNIVERSITÄT HAMBURG [DE]/[DE]
Inventors
  • KHANKISCHPUR, Medhi, Mike
  • PETINA, Olga
  • GEFFKEN, Detlef
  • ERNHOEFER, Dagmar
  • HAYDEN, Michael
Priority Data
62/033,40105.08.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATORS OF CASPASE-6
(FR) MODULATEURS DE CASPASE 6
Abstract
(EN)
The current application relates to a pharmaceutical composition for the treatment or amelioration of a neurological disease, wherein the composition comprises a therapeutically effective amount of a caspase-6 inhibitor which is an arylpropynamide derivative. The composition can be formulated for oral or topical administration, subcutaneous, intravenous, or intramuscular injection, infusion, inhalation, or intrthecal injection.
(FR)
La présente invention concerne une composition pharmaceutique pour le traitement ou l'atténuation d'une maladie neurologique, cette composition comprenant une quantité thérapeutiquement efficace d'un inhibiteur de caspase 6 qui est un dérivé d'arylpropynamide. La composition peut être formulée en vue d'une administration orale ou topique, d'une injection sous-cutanée, intraveineuse ou intramusculaire, d'une perfusion, d'une inhalation ou d'une injection intrathécale.
Latest bibliographic data on file with the International Bureau